Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) - Equities researchers at Leerink Partnrs lifted their Q3 2025 earnings per share (EPS) estimates for shares of Thermo Fisher Scientific in a report issued on Thursday, July 17th. Leerink Partnrs analyst P. Souda now expects that the medical research company will earn $5.49 per share for the quarter, up from their prior forecast of $5.41. The consensus estimate for Thermo Fisher Scientific's current full-year earnings is $23.28 per share. Leerink Partnrs also issued estimates for Thermo Fisher Scientific's Q3 2025 earnings at $5.49 EPS, Q4 2025 earnings at $6.45 EPS, Q4 2025 earnings at $6.45 EPS, FY2025 earnings at $22.32 EPS, Q1 2026 earnings at $5.63 EPS, Q1 2026 earnings at $5.63 EPS, Q2 2026 earnings at $5.94 EPS, Q3 2026 earnings at $6.06 EPS, Q3 2026 earnings at $6.06 EPS and FY2026 earnings at $24.58 EPS.
Other equities research analysts have also recently issued research reports about the company. Barclays cut their price target on Thermo Fisher Scientific from $475.00 to $450.00 and set an "equal weight" rating on the stock in a report on Tuesday, June 24th. UBS Group cut Thermo Fisher Scientific from a "buy" rating to a "neutral" rating and dropped their target price for the stock from $500.00 to $460.00 in a report on Tuesday, July 8th. The Goldman Sachs Group set a $610.00 price objective on Thermo Fisher Scientific and gave the stock a "buy" rating in a research note on Wednesday, April 23rd. Evercore ISI dropped their price target on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating on the stock in a research report on Tuesday, July 8th. Finally, Scotiabank raised Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price target on the stock in a report on Friday, July 11th. Four analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $599.30.
Read Our Latest Report on TMO
Thermo Fisher Scientific Stock Performance
Shares of NYSE TMO traded down $4.46 during mid-day trading on Friday, hitting $420.52. The company had a trading volume of 145,710 shares, compared to its average volume of 2,010,821. Thermo Fisher Scientific has a 12 month low of $385.46 and a 12 month high of $627.88. The stock has a market cap of $158.74 billion, a price-to-earnings ratio of 24.70, a PEG ratio of 2.21 and a beta of 0.77. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.77 and a quick ratio of 1.38. The firm's 50 day simple moving average is $410.13 and its two-hundred day simple moving average is $473.73.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.10 by $0.05. The business had revenue of $10.36 billion for the quarter, compared to analyst estimates of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.15% and a net margin of 15.19%. The business's revenue was up .2% compared to the same quarter last year. During the same period in the prior year, the company posted $5.11 EPS.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently made changes to their positions in the stock. PGGM Investments boosted its holdings in shares of Thermo Fisher Scientific by 106.4% in the 2nd quarter. PGGM Investments now owns 391,920 shares of the medical research company's stock worth $158,908,000 after acquiring an additional 202,045 shares in the last quarter. Broadway Wealth Solutions Inc. grew its holdings in shares of Thermo Fisher Scientific by 23.2% during the second quarter. Broadway Wealth Solutions Inc. now owns 680 shares of the medical research company's stock worth $276,000 after purchasing an additional 128 shares during the last quarter. Westhampton Capital LLC lifted its position in Thermo Fisher Scientific by 7.5% during the 2nd quarter. Westhampton Capital LLC now owns 2,413 shares of the medical research company's stock worth $978,000 after buying an additional 168 shares in the last quarter. Parkside Investments LLC increased its position in Thermo Fisher Scientific by 15.7% in the 2nd quarter. Parkside Investments LLC now owns 16,808 shares of the medical research company's stock valued at $6,815,000 after acquiring an additional 2,280 shares in the last quarter. Finally, Caledonia Investments PLC increased its holdings in shares of Thermo Fisher Scientific by 11.5% in the second quarter. Caledonia Investments PLC now owns 111,767 shares of the medical research company's stock valued at $45,299,000 after purchasing an additional 11,500 shares in the last quarter. 89.23% of the stock is owned by institutional investors.
Insider Activity
In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, April 28th. The stock was sold at an average price of $429.93, for a total transaction of $128,979.00. Following the sale, the executive vice president directly owned 23,167 shares of the company's stock, valued at approximately $9,960,188.31. The trade was a 1.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.33% of the company's stock.
Thermo Fisher Scientific Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a yield of 0.41%. Thermo Fisher Scientific's dividend payout ratio is currently 10.09%.
About Thermo Fisher Scientific
(
Get Free Report)
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
